Trial Profile
The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: A randomized phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Plerixafor (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Acronyms HOVON 107 MOBILIZATION
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 22 May 2015 New trial record